Biosdue secures over 50% of Snia:
This article was originally published in Clinica
Executive Summary
Italian financial company Biosdue, a wholly-owned subsidiary of holding company Bios, has announced that it holds 50.1% of biomedical and chemical group Snia, after launching a bid for full control in February (see Clinica No 984, p 15). Bios already owned a 28.3% majority stake in Snia. The group is expected to focus on its biomedical activities, according to comments made by Emilio Gnutti, head of Bios, in an interview with Italian daily Il Sole 24 Ore. Approximately half of Snia's revenues are generated through its medical technology division.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.